Payment overview · 2025
General Payments
$39,702.70
116 reported records · 23 companies
Healthcare provider profile · identity verified
Kevin Gallagher, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · SHREVEPORT, LA · NPI 1275776718
Verified facts
What the public records show
CMS Open Payments records show Kevin Gallagher, MD received $39,702.70 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica, Welireg, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Imbruvica by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xtandi by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Pomalyst by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xarelto by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 135 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Imbruvica by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WELIREG as an associated drug or biological on 8369 records involving 5216 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Welireg by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19,341.00 | 48.7% | 24 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $10,943.99 | 27.6% | 21 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $7,835.84 | 19.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $266.35 | 0.7% | 9 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $195.43 | 0.5% | 9 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $150.00 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $139.65 | 0.3% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $119.47 | 0.3% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $112.76 | 0.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.80 | 0.3% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $99.99 | 0.2% | 1 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $99.00 | 0.2% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $57.62 | 0.1% | 3 | 2025 |
| Immunocore Limited | Unresolved — no canonical attribution shown | $50.73 | 0.1% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $36.77 | 0.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.09 | 0.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.51 | 0.1% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $19.05 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.51 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.74 | 0.0% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $15.51 | 0.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $13.99 | 0.0% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.90 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,673.13 | 15 |
| Travel and Lodging | $4,940.43 | 12 |
| Food and Beverage | $2,650.16 | 85 |
| Education | $288.98 | 3 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $10,943.99 | 21 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $7,773.04 | 9 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $2,887.44 | 7 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $341.36 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $182.35 | 4 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $160.21 | 7 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Scientific Affairs, LLC | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $119.47 | 6 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.80 | 5 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.80 | 5 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $99.99 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $95.73 | 4 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $83.19 | 4 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $66.11 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $57.62 | 3 | 2025 |
Source payment records
|
|||||
| KIMMTRAK Normalized: kimmtrak |
Drug | Immunocore Limited | $50.73 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $46.28 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $40.47 | 5 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| SYLVANT Normalized: sylvant |
Drug | RECORDATI_RARE_DISEASES_INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| WELIREG welireg |
2025 | Welireg | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xtandi xtandi |
2025 | Xtandi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 135 supporting records · 95 recipient NPIs · example record 1174157420 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | WELIREG open payments reported associated product |
CMS Open Payments — General Payments 8369 supporting records · 5216 recipient NPIs · example record 1237992280 |
Welireg · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Abiraterone Acetate | Abiraterone Acetate | 103 | 16 |
| Eliquis | Apixaban | 89 | 20 |
| Prednisone | Prednisone | 87 | 21 |
| Potassium Chloride | Potassium Chloride | 72 | 34 |
| Pomalyst | Pomalidomide | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 33 |
| Revlimid | Lenalidomide | 56 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 16 |
| Lenalidomide | Lenalidomide | 41 | suppressed |
| Imbruvica | Ibrutinib | 39 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Anastrozole | Anastrozole | 35 | suppressed |
| Gabapentin | Gabapentin | 32 | suppressed |
| Hydroxyurea | Hydroxyurea | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 12 |
| Dexamethasone | Dexamethasone | 28 | 12 |
| Imatinib Mesylate | Imatinib Mesylate | 28 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 14 |
| Xtandi | Enzalutamide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | 12 |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Brukinsa | Zanubrutinib | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Exemestane | Exemestane | 15 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Welireg | Belzutifan | 12 | suppressed |
| Yonsa | Abiraterone Acet,submicronized | 12 | suppressed |
| Zydelig | Idelalisib | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39,702.70 · 116 records | AstraZeneca Pharmaceuticals LP | DATROWAY, ELAHERE, EPKINLY, ERLEADA, Enhertu, FOTIVDA, Fabhalta, IMBRUVICA, IMFINZI, JARDIANCE, KEYTRUDA, KEYTRUDA QLEX, KIMMTRAK, KISQALI, LIBTAYO, LONSURF, LYNPARZA, Lenvima, Nubeqa, Orserdu, PLUVICTO, PROVENGE, Polivy, REBLOZYL, SCEMBLIX, SYLVANT, TALVEY, Tecentriq, Tecentriq Hybreza, Trodelvy, Vanflyta, WELIREG, XT CDX, Xofigo, Xtandi | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error